Johnson & Johnson (NYSE:JNJ) Shares Acquired by Goldstein Advisors LLC

Goldstein Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 26.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,477 shares of the company’s stock after acquiring an additional 947 shares during the period. Goldstein Advisors LLC’s holdings in Johnson & Johnson were worth $654,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Tennessee Valley Asset Management Partners raised its stake in shares of Johnson & Johnson by 3.1% in the 4th quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock worth $418,000 after buying an additional 80 shares in the last quarter. River Road Asset Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $6,093,000. Daiwa Securities Group Inc. raised its stake in shares of Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock worth $46,685,000 after buying an additional 15,490 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Johnson & Johnson by 2.4% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 98,882 shares of the company’s stock worth $15,499,000 after buying an additional 2,345 shares in the last quarter. Finally, Peterson Wealth Services raised its stake in shares of Johnson & Johnson by 9.7% in the 4th quarter. Peterson Wealth Services now owns 25,773 shares of the company’s stock worth $4,040,000 after buying an additional 2,285 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.1 %

Shares of JNJ traded up $1.78 during trading hours on Friday, hitting $164.13. 7,093,429 shares of the company were exchanged, compared to its average volume of 7,299,449. The firm’s 50 day moving average is $153.92 and its 200-day moving average is $153.27. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $167.78. The company has a market cap of $395.01 billion, a PE ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter last year, the company posted $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Morgan Stanley boosted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. TD Securities cut their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, August 5th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.